S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.53 (-2.55%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.53 (-2.55%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.53 (-2.55%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.53 (-2.55%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
Log in
NASDAQ:SLNO

Soleno Therapeutics Stock Forecast, Price & News

$1.82
-0.14 (-7.12 %)
(As of 09/23/2020 02:25 PM ET)
Add
Compare
Today's Range
$1.81
Now: $1.83
$1.98
50-Day Range
$1.72
MA: $1.94
$2.16
52-Week Range
$1.18
Now: $1.83
$4.39
Volume8,694 shs
Average Volume545,983 shs
Market Capitalization$145.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More
Soleno Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.41 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share

Profitability

Net Income$-30,770,000.00

Miscellaneous

Employees9
Market Cap$145.26 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$1.82
-0.14 (-7.12 %)
(As of 09/23/2020 02:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

How has Soleno Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLNO shares have decreased by 25.9% and is now trading at $1.86.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Soleno Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Soleno Therapeutics
.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Soleno Therapeutics
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics Inc (NASDAQ:SLNO) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.05.
View Soleno Therapeutics' earnings history
.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics's stock reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

3 brokerages have issued 1-year price targets for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Soleno Therapeutics' share price to reach $9.33 in the next twelve months. This suggests a possible upside of 401.8% from the stock's current price.
View analysts' price targets for Soleno Therapeutics
.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,550,000 shares, a decrease of 13.9% from the August 15th total of 1,800,000 shares. Based on an average trading volume of 896,200 shares, the days-to-cover ratio is presently 1.7 days.
View Soleno Therapeutics' Short Interest
.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Opko Health (OPK), Vaxart (VXRT), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Acasti Pharma (ACST) and Dynavax Technologies (DVAX).

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO & Director (Age 49)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 57)
  • Mr. David D. O'Toole, Consultant (Age 60)
  • Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 69)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (16.61%), Oracle Investment Management Inc. (8.21%), Granite Point Capital Management L.P. (4.92%), AWM Investment Company Inc. (3.47%), Point72 Asset Management L.P. (1.79%) and Trellus Management Company LLC (0.82%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Bioasia Mangement Llc, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Ventures Fund V LP Vivo and Vivo Ventures V, Llc.
View institutional ownership trends for Soleno Therapeutics
.

Which major investors are selling Soleno Therapeutics stock?

SLNO stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., and Trellus Management Company LLC. Company insiders that have sold Soleno Therapeutics company stock in the last year include Ventures Fund V LP Vivo, and Vivo Ventures V, Llc.
View insider buying and selling activity for Soleno Therapeutics
.

Which major investors are buying Soleno Therapeutics stock?

SLNO stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Granite Point Capital Management L.P., AWM Investment Company Inc., Point72 Asset Management L.P., Baird Financial Group Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, and Larry N Feinberg.
View insider buying and selling activity for Soleno Therapeutics
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $1.86.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $148.04 million. The company earns $-30,770,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Soleno Therapeutics employs 9 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.